Trials / Completed
CompletedNCT00447005
Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors
A Phase 1 Study Of AG-013736 (Axitinib) In Japanese Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the clinically recommended dose of AG-013736 (Axitinib) in Japanese patients by reviewing the safety of AG-013736 (Axitinib) following single and multiple dosing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Axitinib (AG-013736) | AG-013736 5mg twice daily \[BID\] |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2007-03-13
- Last updated
- 2012-05-23
- Results posted
- 2012-03-26
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00447005. Inclusion in this directory is not an endorsement.